Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta‐analysis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Summary: The objective of this article was to estimate the risk of discontinuation due to adverse events in trials of orlistat, sibutramine and rimonabant. Medline, EMBASE, the Cochrane controlled trials register and reference lists of identified articles were searched from 1990 to May 2008. All randomized placebo‐controlled trials of 12–24 months of duration on adults using licensed doses were included. Studies/study arms were excluded if they evaluated weight maintenance after weight loss. Trials were identified, subjected to inclusion and exclusion criteria and reviewed. Data on participants, interventions and discontinuation were extracted and trials rated for quality based on established criteria. A random effects model was used to estimate pooled risk ratios, risk differences and number needed to harm (NNH). A total of 28 trials met the inclusion criteria (16 orlistat, 7 sibutramine and 5 rimonabant). The risk ratios for discontinuation due to adverse events were significantly elevated for rimonabant (2.00; 1.66–2.41) and orlistat (1.59; 1.21–2.08), but not sibutramine (0.98, 0.68–1.41). Compared with placebo, the risk difference was the largest for rimonabant (7%, 5–9%; NNH 14, 11–19), followed by orlistat (3%, 1–4%; NNH 39, 25–83), while no significant difference was seen for sibutramine (0.2%, −3 to 4%; NNH 500). The most common adverse events leading to withdrawal were gastrointestinal for orlistat (40%) and psychiatric for rimonabant (47%). Corresponding information was unavailable for sibutramine. In conclusion, available weight loss drugs differ markedly regarding risk of discontinuation due to adverse events, as well as in underlying causes of these events. Given the large number of patients eligible for treatment, the low NNH for rimonabant is a concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · cited 2×
“…per arm) 20-mg sibutramine McMahon et al., 2000 (48) Minimal behavioural intervention 224 (150,74 per arm) 20-mg sibutramine ORLISTAT (360 mg d-1) Torgerson et al., 2004 (19) Lifestyle change 3305 (1650,1655 per arm) Only dropout after 4 years Lucas et al., 2003 (49) Reduced diet 444 (256, 188…”
BackgroundEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 3×
“7) 162 (16) 221 (21) Dropout due to Aes† N (studies reporting withdrawal due to AE) 2925 2019 576 416 3532 3084”
BackgroundSjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · cited 1×
“Orlistat is a lipase inhibitor, sibutramine a noradrenaline-serotonindopamine reuptake inhibitor and rimonabant is an endocannabinoid receptor antagonist (4).”
BackgroundAls-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746 · cited 3×
“As almost all studies were either conducted or funded by pharmaceutical companies, and all studies showed a significant effect for the primary outcome (weight loss), publication bias may be suspected as trials funded by for-profit organizations are more likely to report positive findings than trials funded by not-for-…”
Background
Cited by
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
The link between stress and feeding behaviour
Maniam, J., & Morris, M. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.017 · Cited by 255
Johansson, K., Hemmingsson, E., Harlid, R., Trolle Lagerros, Y., Granath, F., Rossner, S., & Neovius, M. (2011) · BMJ · doi:10.1136/bmj.d3017 · Cited by 98
Self-citationGrube, B., Chong, P., Lau, K., & Orzechowski, H. (2013) · Obesity · doi:10.1002/oby.20244 · Cited by 83
“However, this pharmacotherapy is associated with gastrointestinal (GI) side effects such as fecal incontinence, flatus with discharge, oily spotting (13,16-17), and liver injury (18).”
BackgroundPucci, M., Micioni Di Bonaventura, M. V., Vezzoli, V., Zaplatic, E., Massimini, M., Mai, S., Sartorio, A., Scacchi, M., Persani, L., Maccarrone, M., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00523 · Cited by 38
Metadata
- Authors
- Johansson, K., Neovius, K., DeSantis, S. M., Rössner, S., & Neovius, M.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2009-08-26
- Volume
- 10
- Issue
- 5
- Pages
- 564-575
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W1995734772
- Cited by
- 86
- References
- 17
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta‐analysis. https://app.cochat.ai/papers/10.1111/j.1467-789x.2009.00581.x
- The paper
- Johansson, K., Neovius, K., DeSantis, S. M., Rössner, S., & Neovius, M. (2009). Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta‐analysis. Obesity Reviews. https://doi.org/10.1111/j.1467-789x.2009.00581.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.